Predicting patient-specific quality assurance outcomes in helical tomotherapy using plan complexity and 3D dose-distribution radiomics
Frontiers in Oncology · 20.07.2026 · 16
DOI: 10.3389/fonc.2026.1883024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.07.2026. Verfasst von Xiaoli Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical Univers…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pretreatment patient-specific quality assurance (PSQA) for helical tomotherapy (HT) is time-consuming and resource-intensive. Machine-learning-based screening tools may help prioritize measurement-based QA resources. This study investigated whether combining plan complexity descriptors with 3D dose-distribution radiomic features could improve the prediction of HT plan deliverability. A total of 498 clinical HT plans from two institutions were retrospectively analyzed, including 286 plans from Institution 1 and 212 from Institution 2. For each plan, 72 plan complexity features and 851 dose-distribution radiomic features were extracted. Support vector machine classifiers were developed separately for each institution using three feature sets: plan complexity features alone, dose-distribution radiomic features alone, and their combination. Model performance was evaluated on independent test sets using receiver operating characteristic analysis, with ground−truth PSQA outcomes defined according to preset gamma passing−rate thresholds. Across both institutions and both gamma criteria, the hybrid model achieved the best discrimination. Its AUCs were 0.774 and 0.938 for γ 3%/2 mm in Institutions 1 and 2, respectively, and 0.820 and 0.825 for γ 2%/2 mm. The most informative predictors included variables from both feature domains, and the hybrid model achieved higher AUCs than models using either domain alone. Additional analyses, including an exact permutation test and a bidirectional cross-institution evaluation, showed that the high AUCs were unlikely to result from chance but highlighted limited transferability across centers. These findings suggest that integrating plan complexity and 3D dose-distribution radiomic features may support risk-adapted pretreatment PSQA screening for HT. However, external multi-institution validation and prospective workflow assessment are required before considering clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Jin, X., Xiao, X., Guo, R., Chen, T., & Hu, C. (2026). Predicting patient-specific quality assurance outcomes in helical tomotherapy using plan complexity and 3D dose-distribution radiomics. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1883024
Vancouver
Jin X, Xiao X, Guo R, Chen T, Hu C. Predicting patient-specific quality assurance outcomes in helical tomotherapy using plan complexity and 3D dose-distribution radiomics. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1883024
BibTeX
@article{Jin2026,
author = {Jin, Xiaoli and Xiao, Xiaoguang and Guo, Rui and Chen, Tao and Hu, Cairong},
title = {Predicting patient-specific quality assurance outcomes in helical tomotherapy using plan complexity and 3D dose-distribution radiomics},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1883024}
}
EUVIMED